Could a break from teclistamab be safe for myeloma patients?

NCT ID NCT05932680

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with multiple myeloma who have responded very well to teclistamab can safely stop taking it for a while. Instead of staying on the drug indefinitely, participants who have had a good response for 6-9 months will pause treatment and be closely monitored. If the cancer shows signs of returning, they will restart teclistamab. The goal is to see if this drug holiday works as well as continuous therapy, while reducing side effects like infections and the risk of the cancer becoming resistant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teclistamab
What this could lead to: If successful, this could allow some multiple myeloma patients to take a break from teclistamab without the cancer returning quickly, reducing infections and drug resistance.
What could go wrong: This is a small, early-phase study (75 people) without a comparison group. The cancer may return sooner than expected, and not all patients will benefit from stopping therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

Abramson Cancer Center at University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Columbia University
RECRUITING

New York, New York, 10032-3702, United States
Thomas Jefferson University, Honickman Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Arkansas for Medical Sciences
RECRUITING

Little Rock, Arkansas, 72205, United States
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.